Neurobiological Reports End of Phase II Meeting With FDA Over Viprinex

Neurobiological Technologies has reported on an End of Phase II meeting with the FDA regarding Viprinex, a product in clinical development for the treatment of acute ischemic stroke.

As a result of the meeting, the company continues to move forward with its plan to commence a Phase III program this summer.

Viprinex (Ancrod) has been studied in more than 2,000 patients in various clinical studies in the U.S. and Europe. The prior development work on Viprinex was conducted by Knoll AG, prior to its acquisition by Abbott in 2001.

If successful, the company believes that Viprinex may have the potential to double the available treatment window following the onset of stroke symptoms. Currently, the only available therapy for stroke must be administered within the initial three hours, significantly limiting the number of patients that may be treated.